Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.98 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.98 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.98 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.98 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.98 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.98 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 0.98 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 0.98 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.82 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.82 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL2554008 | 1.00 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29349808 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29351376 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.98 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29555444 | 0.98 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2552684 | 0.96 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.93 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5086313 | 0.92 | RAF1 (0.87) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL22627130 | 0.91 | RAF1 (0.85) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117427071-A | Application of Regorafenib monohydrate in preparation of anti-new coronavirus drugs | 上海交通大学医学院 | 2024-01-23 | — | — | CN | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4558505-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025100428-A1 | COMBINATION OF ANTI-CD147 ANTIBODY AND ANOTHER ANTITUMOR AGENT | 第一三共株式会社 | 2025-05-15 | — | — | WO | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-115112777-B | Method for analyzing related substances of regorafenib intermediate | 南京正大天晴制药有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2022197898-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114945378-A | Feeder-layer and feeder-layer-free stem cell culture systems for stratified epithelial stem cells and uses related thereto | 休斯敦大学体系 | 2022-08-26 | — | — | CN | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-4041259-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022164789-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS | SCHRÖDINGER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-4021449-A1 | STING MODULATORS, COMPOSITIONS, AND METHODS OF USE | University of South Florida (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-108349969-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阵列生物制药公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022055963-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | RAF1 127/4885BRAF 3/4885KDR 517/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | RAF1 4809/4885BRAF 4655/4885KDR 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.